Alefacept in corticosteroid refractory graft versus host disease: Early results indicate promising activity

Journal of Dermatological Treatment

Volumn 18, Issue 1, 2007, Pages 13-18

  Toor, Amir A ^a   Stiff, Patrick J ^a   Nickoloff, Brian J ^a   Rodriguez, Tulio ^a   Klein, Jared L ^a   Gordon, Kenneth B ^b,c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Division of Dermatology   (United States)

Author keywords

Alefacept; CD2; Corticosteroid refractory; Graft versus host disease; T cells

Indexed keywords

ALEFACEPT; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ITRACONAZOLE; METHYLPREDNISOLONE; VALACICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GENE TARGETING; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOHISTOCHEMISTRY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIGENS, CD2; BONE MARROW TRANSPLANTATION; DERMATOLOGIC AGENTS; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID, CHRONIC; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 33947162398     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601121045     Document Type: Article

References (36)

1. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175-81.
2. Elmaagacli AH, Basoglu S, Peceny R, Trenschel R, Ottinger H, Lollert A, et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood. 2002;99:1130-5.
3. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant. 2002;8:387-94.
4. Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7:265-73.
5. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft-versus-host disease: A randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48-51.
6. MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NK, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:40-6.
7. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95:83-9.
8. Deeg J, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001;98:2052-8.
9. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:1224-6.
10. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 2002;99:2712-19.
11. Wingren AG, Parra E, Varga M, Kalland T, Sjogren HO, Hedlund G, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol. 1995;15:235-53.
12. Damle NK, Klussman K, Linsley PS, Aruffo A. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol. 1992;148:1985-92.
13. Bohmig GA, Kovarik J, Holter W, Pohanka E, Zlabinger GJ. Specific down-regulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-1/ICAM-1 in vitro. J Immunol. 1994;152:3720-8.
14. Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG, Nadler LM. CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. J Exp Med. 1994;180:1665-73.
15. Da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002;168:4462-71.
16. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Dupont B, Good RA, et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981;2:327-31.
17. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983;61:341-8.
18. Kernan NA, Flomenberg N, Collins NH, O'Reilly RJ, Dupont B. Quantitation of T lymphocytes in human bone marrow by a limiting dilution assay. Transplantation. 1985;40:317-22.
19. Wiesneth M, Schreiner T, Friedrich W, Muller S, Maccari B, Erne E, et al. Combined CD34 positive plus CD2 negative selection for effective T-cell depletion as GvHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation. Transfus Sci. 1996;17:629-35.
20. Cavazzana-Calvo M, Bordigoni P, Michel G, Esperou H, Souillet G, Leblanc T, et al. A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: Prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Societe Francaise de Greffe de Moelle Osseuse. Br J Haematol. 1996;93:131-8.
21. Cavazzana-Calvo M, Jabado N, Bordigoni P, Michel G, Haddad E, Mechinaud F, et al. In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemia. Leuk Lymphoma. 1997;28:103-12.
22. Spitzer TR, McAfee SL, Dey BR, Colby C, Hope J, Grossberg H, et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation. 2003;75:1748-51.
23. Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S, et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2005;128:351-9.
24. Xu Y, Kolber-Simonds D, Hope JA, Bazin H, Latinne D, Monroy R, et al. The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion. Clin Exp Immunol. 2004;138:476-83.
25. Przepiorka D, Phillips GL, Ratanatharathorn V, Cottler-Fox M, Sehn LH, Antin JH, et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood. 1998;92:4066-71.
26. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Tsirigotis P, Gesundheit B, et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: A preliminary report. Bone Marrow Transplant. 2005;36:1097-101.
27. Elliott CJ, Sloane JP, Pallett CD, Sanderson KV. Cutaneous leucocyte composition after human allogeneic bone marrow transplantation: Relationship to marrow purging, histology and clinical rash. Histopathology. 1988;12:1-16.
28. Roy J, Platt JL, Weisdorf DJ. The immunopathology of upper gastrointestinal acute graft-versus-host disease. Lymphoid cells and endothelial adhesion molecules. Transplantation. 1993;55:572-8.
29. Weisdorf SA, Roy J, Snover D, Platt JL, Weisdorf DJ. Inflammatory cells in graft-versus-host disease on the rectum: Immunopathologic analysis. Bone Marrow Transplant. 1991;7:297-301.
30. Diamond DJ, Chang KL, Jenkins KA, Forman SJ. Immunohistochemical analysis of T cell phenotypes in patients with graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation. 1995;59:1436-44.
31. Thiele J, Kvasnicka HM, Beelen DW, Welter A, Schneider S, Leder LD, et al. Reconstitution of the CD45RO(+) and CD20(+) lymphoid marrow population following allogeneic bone marrow transplantation for Ph(+) CML. Bone Marrow Transplant. 2001;27:425-31.
32. Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT, et al. Severe chronic graft-versus-host disease is characterized by a preponderance of CD4+ effector memory cells relative to central memory cells. Blood. 2004;103:3986-8.
33. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-55.
34. Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K, et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol. 2003;33:666-75.
35. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol. 2003;49:816-25.
36. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A. Alefacept Clinical Study Group. Treatment of psoriasis with alefacept: Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003;139:1563-70.